Effect of telmisartan, angiotensin‐converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs

Abstract

Background: The use of telmisartan (TEL), an angiotensin-receptor blocker, for the control of systemic hypertension and proteinuria in dogs has not been reported extensively in a clinical setting.Objectives: To determine the effects of an angiotensin-converting enzyme inhibitor (ACEi) alone, ACEi in combination with TEL, or TEL alone on systolic blood pressure and proteinuria in dogs with protein losing nephropathy (PLN).Animals: Forty-two client-owned dogs being treated for PLN.Methods: Retrospective observational study of medical records of dogs at a university teaching hospital from 2012 to 2018 with the use of benazepril or enalapril alone, TEL alone, or both modalities for the management of PLN. Noninvasive blood pressure and urine protein to creatinine ratio (UPC) were compared among the treatment groups over time. A multivariable mixed-effects linear regression model followed by post hoc analysis was used to estimate the marginal means and differences between the treatment groups.Results: In comparison to group ACEi alone, combination treatment of an ACEi with

Association between serum fibroblast growth factor‐23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease

“…Moreover, our study was retrospective and included dogs that were already being treated for proteinuria, systemic hypertension or both, most of which were treated with telmisartan. The efficacy of telmisartan on proteinuria and blood pressure recently was found to be superior to that of angiotensin converting enzyme inhibitors 56,57 . Therefore, telmisartan could have influenced the effects of proteinuria and systemic hypertension on the progression of CKD 33,34,55 …”

“…The efficacy of telmisartan on proteinuria and blood pressure recently was found to be superior to that of angiotensin converting enzyme inhibitors. 56 , 57 Therefore, telmisartan could have influenced the effects of proteinuria and systemic hypertension on the progression of CKD. 33 , 34 , 55 …”

The use of telmisartan in combination therapy in the management of nephrotic syndrome due to non‐immune‐mediated glomerulonephropathy in a young cat

“…published information on this subject. 9 Due to the variety of attempted medical treatments, the only conclusion that could be drawn regarding treatment was the benefit of immunosuppressing cats with immune-mediated glomerular disease. Survival time for 17 cases of immune-mediated glomerular disease was a median of 193 days (range 5-1235), and for 9 cases of non-immune-mediated glomerular disease was a median of 74 days (range 3-1848).…”

“…Serum biochemistry revealed hypoalbuminaemia (11.3 g/L; 25-45), with normal globulin (30 g/L; 25-45), hypercholesterolemia (9 mmol/L; 2.2-4), increased urea of 17.7 mmol/L (<9.9) and hyperkalaemia (5.84 mmol/L; 3.5-5.5). Creatinine was normal (89 µmol/L; 80-203) and symmetric dimethylarginine (SDMA) was normal (9 µg/dl; [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. Haematology showed lymphocytosis (13.28 × 10 9 /L; 0.85-5.85).…”

“…The UPC was determined by quantitative measurement at a reference laboratory. Due to the magnitude of the proteinuria, a repeat UPC determination to confirm persistent proteinuria was deemed unnecessary, as per published guidelines 9 …”